Multinational drug company rebutted bridging clinical study.

The multinational pharmaceutical corporations strongly resisted against the KFDA's bridging study program recently announced in public, which should be performed only for Korean ethnic patients living in domestic or overseas locations as an improvement of the current registration system for a new drug developed by foreign companies.

The current new drug registration provision only requires ...